Power Up Your Brain
Power Up Your Brain
by David Perlmutter, MD, FACN, ABIHM &
Albert Villoldo, Ph.D
Raise a Smarter Child by Kindergarten
Raise a Smarter Child by Kindergarten
by David Perlmutter, MD, FACN, ABIHM
The Better Brain Book


by David Perlmutter, MD, FACN, ABIHM
Read Dr. Perlmutter's
articles at

Statins Show Dramatic Drug And Cell Dependent Effects In The Brain

October 31st, 2009

From ScienceDaily.com:

Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia. However, a study in the October Journal of Lipid Research finds that similar statin drugs can have profoundly different effects on brain cells -both beneficial and detrimental.
These findings reinforce the idea that great care should be taken when deciding on the dosage and type of statin given to individuals, particularly the elderly.
John Albers and colleagues compared the effects of two commercially used statins, simvastatin and pravastatin, on two different types of brain cells, neurons and astrocytes (support cells that help repair damage). By directly applying the drugs to cells as opposed to administering them to animals, they could eliminate differences in the drugs’ ability to cross the blood-brain barrier as a reason for any differing effects. Albers and colleagues looked at the expression of genes related to neurodegeneration, and found that indeed, despite using biologically equivalent drug concentrations, differences were seen both between cells, and between drugs; for example, simvastatin reduced the expression of the cholesterol transporter ABCA1 by approximately 80% in astrocytes, while pravastatin lowered expression by only around 50%. Another interesting difference was that while both statins decreased expression of the Tau protein -associated with Alzheimer’s disease — in astrocytes, they increased Tau expression in neurons; pravastatin also increased the expression of another Alzheimer’s hallmark, amyloid precursor protein (APP).
While increased levels of these two proteins may account for potential risks of disease, Albers and colleagues also note that large decreases in cholesterol proteins like ABCA1 should be considered. Brain cholesterol levels tend to be reduced in elderly people, and in such individuals the long-term effects of statin therapy could lead to transient or permanent cognitive impairment.

More than half million kids get bad drug reactions

October 20th, 2009

From WashingtonPost.com:

More than half a million U.S. children yearly have bad reactions or side effects from widely used medicines that require medical treatment and sometimes hospitalization, new research shows.

Children younger than age 5 are most commonly affected. Penicillin and other prescription antibiotics are among drugs causing the most problems, including rashes, stomachaches and diarrhea.

Parents should pay close attention when their children are started on medicines since “first-time medication exposures may reveal an allergic reaction,” said lead author Dr. Florence Bourgeois, a pediatrician with Children’s Hospital in Boston.

Doctors also should tell parents about possible symptoms for a new medication, she said.

The study appears in October’s Pediatrics, released Monday.

It’s based on national statistics on patients’ visits to clinics and emergency rooms between 1995 and 2005. The number of children treated for bad drug reactions each year was mostly stable during that time, averaging 585,922.

Bourgeois said there were no deaths resulting from bad reactions to drugs in the data she studied, but 5 percent of children were sick enough to require hospitalization.

The study involved reactions to prescribed drugs, including accidental overdoses. They were used for a range of ailments including ear infections, strep throat, depression and cancer. Among teens, commonly used medicines linked with troublesome side effects included birth control pills. Bad reactions to these pills included menstrual problems, nausea and vomiting.

Children younger than 5 accounted for 43 percent of visits to clinics and emergency rooms; followed by teens aged 15 to 18, who made up about 23 percent of the visits.

Similar numbers of hospitalized children – about 540,000 yearly – also have bad reactions to drugs, including side effects, medicine mix-ups and accidental overdoses, recent government research suggests.

The new report indicates children at home are just as vulnerable.

Michael Cohen, president of the Institute for Safe Medication Practices, said a common problem involves giving young children liquid medicine. Doses can come in drops, teaspoons or milliliters, and parents may mistakenly think those amounts are interchangeable.

Cohen said doctors should be clear about doses and parents should be sure before leaving the pharmacy that they understand exactly how to give liquid medicine.

The study was funded by the National Library of Medicine and the National Institute of Child Health and Human Development.

Psychiatrists Can Now Predict An Individual Patient’s Response To A Drug

September 30th, 2009

From ScienceDaily.Com:

The first in a new generation of gene microarrays, computer chips that chemically or electrically express DNA, can predict how a person’s body will metabolize about 25 percent of drugs on the market, including most antipsychotic medications. The chip tests for mutations in genes that break down drugs. Molecular biologists say that slow metabolizers may be susceptible to side effects, while fast metabolizers may not find a drug effective.

AUGUSTA, Ga. — It can be a game of Russian roulette. When doctors try out different meds on patients, they don’t always know how they’ll respond — and the wrong guess can have deadly consequences. Now, there’s a new way to tell how people break down certain drugs, paving the way for personalized medicine.

Playing tug of war with her horse, Shilo, is the same kind of struggle 62-year-old Lynne Tollison has always had with doctors. She says, “This is the classic answer: ‘She obviously takes a lot of medication, and her body builds up tolerances,’ like I’m a drug addict.”

Pain medications haven’t worked for Tollison’s arthritis, and side effects prevented her from taking a drug for bipolar disorder. “You get to the point where you don’t go to a doctor or dentist when you need to go, because what they give you is not going to help, so you don’t go!”

But now, a first-of-its kind gene chip test is solving years of medical mystery. It tells doctors how a person processes about 25 percent of drugs on the market, including most antipsychotic meds.

Psychiatrist Adriana Foster, of the Medical College of Georgia in Augusta, says, “Our slogan is start low and go slow, but patients can’t always afford that because they could be terribly depressed and at risk of suicide.”

Here’s how the test works. First, blood is drawn and DNA is extracted. Then scientists isolate the two genes that break down drugs and look for mutations.

Doctors hope the test will pave the way for a new generation of medicine.

“We have been, you know, waiting for these kind of things for a long time, and now it’s here,” Zixuan Wang, a microbiologist at Medical College of Georgia, tells DBIS.

For Tollison, who just found out she is a poor metabolizer, it means validation and hopefully finding effective treatments that will allow her to take care of her family. “I have to struggle to keep myself together sometimes, so that would be wonderful,” she says. If a person is a poor metabolizer, they may be susceptible to side effects and will stop taking a much-needed drug because of them. If a person is a fast metabolizer, the drug may not work, and a depressed patient could commit suicide in that time. Right now the gene chip test costs between $600 and $1,000, but in the future it could be something insurance would cover. And the researchers say it could ultimately be cost-effective as there would be fewer trial-and-error prescriptions made.

BACKGROUND: Researchers are using a new test that looks at how each person’s body digests, absorbs and circulates drugs. This will allow doctors to prescribe carefully tailored dosages, without weeks of trial and error. This in turn will help patients get the best treatment and lower side effects. It’s one of the first steps toward personalized medicine. The test will initially be used to determine the best dosages of commonly used psychiatric drugs. A second test is being developed to look at how the body processes the most common drugs used in chemotherapy.

IMPROVED DRUG EFFICACY: The bloodstream is the primary means for transporting drugs through the body, and the liver is the central places the body processes — or “metabolizes” — drugs. A drug’s effect depends less on chemistry than on the way it navigates through the body: being broken down by the liver, absorbed by the intestines and stored in fat cells. And that process can be affected by how each person’s body uses drugs differently.

THE ROLE OF METABOLISM: The body’s processing, or metabolic, rate changes from person to person, depending on a wide variety of factors: age, sex, and amount of lean body mass, for example. If someone has a low metabolism, the drug will not be broken down properly, staying in the liver at high concentrations and causing side effects. Side effects from medications are the fourth leading cause of death in the United States. This kind of patient needs lower doses of the drug. On the other hand, someone with a very fast metabolism will break the drug down so quickly that it will not be effective. Those people require higher doses. Even high amounts of otherwise beneficial vitamins and minerals can lead to toxic side effects.

HOW IT WORKS: Tiny labs-on-a-chip (called microarrays) have been on the market for several years. The AmpliChip CYP450 test analyzes two genes involved in metabolizing about 25 percent of all drugs, including many psychiatric drugs. A blood sample is inserted into the chip, which rapidly searches the sample for telltale genetic variations. Microarrays are an example of microelectro-mechanical systems. MEMs integrate electronic and moving parts onto a microscopic silicon chip, making them ideal for new sensor technology. A MEMS device is usually only a few micrometers wide; for comparison, a human hair is 50 micrometers wide.

ABOUT MICROFLUIDICS: Microfluidics studies how fluids behave at microscopic levels: volumes of water, for example, that are thousands of times smaller than a single droplet. At these size scales, tiny effects that wouldn’t be noticeable on a large scale play a much larger role. By understanding these effects, scientists can use them manipulate fluids on the microscopic scale. This has led to such beneficial technologies as ink jet printers and labs-on-a-chip for fast and cheap DNA sequencing.

Study: Drug Combos May Raise Breast Cancer Risk

September 27th, 2009

Study: Some antidepressants interfere with tamoxifen, raise risk of breast cancer’s return

From ABCNews.com:

Breast cancer survivors risk having their disease come back if they use certain antidepressants while also taking the cancer prevention drug tamoxifen, worrisome new research shows.

About 500,000 women in the United States take tamoxifen, which cuts in half the chances of a breast cancer recurrence. Many of them also take antidepressants for hot flashes, because hormone pills aren’t considered safe after breast cancer.

Doctors have long known that some antidepressants and other medicines can lower the amount of tamoxifen’s active form in the bloodstream. But whether this affects cancer risk is unknown.

The new study, reported Saturday at a cancer conference in Florida, is the largest to look at the issue. It found that using these interfering drugs — including Prozac, Paxil or Zoloft — can virtually wipe out the benefit tamoxifen provides.

Many doctors question the magnitude of harm from combining these medicines, and a second, smaller study suggests it may not be very large.

But the bottom line is the same: Not all antidepressants pose this problem, and women should talk to their doctors about which ones are best.

“There are other alternatives we can consider” that are safer, said Dr. Eric Winer, breast cancer chief at the Dana-Farber Cancer Center in Boston.

He had no role in the study, which was done by Medco Health Solutions Inc., a large insurance benefits manager. Researchers used members’ medical records to identify 353 women taking tamoxifen plus other drugs that might interfere with it, and 945 women taking tamoxifen alone. Those taking a drug combo did so for about a year on average.

Next, researchers checked to see how many were treated for second cancers in the following two years. Breast cancer recurred in about 7 percent of women on tamoxifen alone, and in 14 percent of women also taking other drugs that could interfere — mainly the antidepressants Paxil and Prozac, and, to a lesser extent, Zoloft.

If women want to take an antidepressant, “you probably want to stay away from those three,” said Medco’s chief medical officer, Dr. Robert Epstein.

No greater breast cancer risk was seen in women taking the antidepressants Celexa, Lexapro or Luvox with tamoxifen, and there are reasons to think that other antidepressants may be safe as well, Epstein said.

A second study led by Dr. Vincent Dezentje of Leiden University Medical Center in the Netherlands found little risk from combining tamoxifen and popular antidepressants. However, only 150 women in the study took such combos for more than two months, and they were compared to women taking combos for a shorter time — not to women using tamoxifen alone.

The Dutch and Medco studies were presented at a meeting of the American Society of Clinical Oncology.

The federal Food and Drug Administration has been considering a change to tamoxifen’s label to warn about the antidepressants drugs and a gene variation some women have that can make tamoxifen less effective. An advisory panel unanimously recommended a change in 2006, but the agency is still considering it.

“This is a very controversial area,” said Dr. Claudine Isaacs, a breast specialist at Georgetown University’s Lombardi Comprehensive Cancer Center. “Until these data are absolutely clear, I would avoid drugs that impact on tamoxifen metabolism.”

Breast cancer is the most common major cancer in American women. More than 182,000 new cases were diagnosed last year, and it caused nearly 41,000 deaths.

Some antibiotics can cause double vision

September 4th, 2009

From LATimes.com:

Add one more side effect to the growing list of adverse events associated with the family of antibiotics known as fluoroquinolones: double vision. The powerful drugs are widely used to treat infections, including bacterial or chronic bronchitis, pneumonia, sinusitis, urinary infections and some skin infections. But they have been associated with a wide variety of side effects, including tendinitis (an inflammation of tendons) and tendon rupture, gastrointestinal problems, liver damage, central nervous system problems and skin phototoxicity. Although most of the side effects have been mild and self-limiting, at least five of the drugs — gatifloxacin, grepafloxacin, temafloxacin, trovafloxacin and alatrofloxacin — have been removed from the market because of the problems.

Spurred by sporadic reports of eye problems associated with the drugs, Dr. Frederick W. Fraunfelder and Dr. Frederick T. Fraunfelder, ophthalmologists at the Casey Eye Institute at the Oregon Health and Science University in Portland, compiled all eye-related adverse event reports related to the drugs between 1986 and 2009. They reported in the September issue of the journal Ophthalmology that they found 171 case reports of double vision (diplopia) — 76 in men, 91 in women and four for which no sex was reported. There were 75 cases linked to ciprofloxacin (Cipro), 9 linked to gatifloxacin (Tequin), 20 to levofloxacin (Levaquin), 16 to moxifloxacin (Avelox), 11 to norfloxacin (Noroxin) and 40 to ofloxacin (Floxin). The number of cases were roughly proportional to the number of prescriptions written for each drug, suggesting that the problem involves the class of drugs rather than a particular product. Although the overall numbers seem small, experts note that perhaps fewer than 10% of such complications are routinely reported to monitoring bodies.

There appeared to be no long-term effects on the eye. In the 53 reported cases in which the antibiotic was withdrawn, vision returned to normal quickly. In five of those cases where the patient was then given the drug again, the problem returned.

There is no clear reason why the problem occurred, the authors said. One good possibility is that the drug affected tendons controlling the eye, interfering with their ability to focus.